Mesothelin-targeted immunotherapies for malignant pleural mesothelioma

doi:10.3978/j.issn.2225-319X.2012.10.03

. 2012 Nov;1(4):466-71.

doi: 10.3978/j.issn.2225-319X.2012.10.03.

Mesothelin-targeted immunotherapies for malignant pleural mesothelioma

Jonathan Villena-Vargas¹, Prasad S Adusumilli

Affiliations

PMID: 23977538
PMCID: PMC3741795
DOI: 10.3978/j.issn.2225-319X.2012.10.03

Mesothelin-targeted immunotherapies for malignant pleural mesothelioma

Jonathan Villena-Vargas et al. Ann Cardiothorac Surg. 2012 Nov.

. 2012 Nov;1(4):466-71.

doi: 10.3978/j.issn.2225-319X.2012.10.03.

Authors

Jonathan Villena-Vargas¹, Prasad S Adusumilli

Affiliation

¹ Center for Cell Engineering and Department of Surgery, Thoracic Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

PMID: 23977538
PMCID: PMC3741795
DOI: 10.3978/j.issn.2225-319X.2012.10.03

No abstract available

PubMed Disclaimer

Cited by

Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Santin AD, Vergote I, González-Martín A, Moore K, Oaknin A, Romero I, Diab S, Copeland LJ, Monk BJ, Coleman RL, Herzog TJ, Siegel J, Kasten L, Schlicker A, Schulz A, Köchert K, Walter AO, Childs BH, Elbi C, Bulat I. Santin AD, et al. Int J Gynecol Cancer. 2023 Apr 3;33(4):562-570. doi: 10.1136/ijgc-2022-003927. Int J Gynecol Cancer. 2023. PMID: 36564099 Free PMC article. Clinical Trial.
Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P, Nandigama R, Eul B, Huber M, Kobold S, Seeger W, Grimminger F, Savai R. Kandra P, et al. Front Immunol. 2022 Jun 2;13:903562. doi: 10.3389/fimmu.2022.903562. eCollection 2022. Front Immunol. 2022. PMID: 35720364 Free PMC article. Review.
The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.
Zhang J, Wang L. Zhang J, et al. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819831068. doi: 10.1177/1533033819831068. Technol Cancer Res Treat. 2019. PMID: 30798772 Free PMC article.
Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.
White M, Freistaedter A, Jones GJB, Zervos E, Roper RL. White M, et al. PLoS One. 2018 Feb 23;13(2):e0193131. doi: 10.1371/journal.pone.0193131. eCollection 2018. PLoS One. 2018. PMID: 29474384 Free PMC article.
Improving theranostics in pancreatic cancer.
King J, Bouvet M, Singh G, Williams J. King J, et al. J Surg Oncol. 2017 Jul;116(1):104-113. doi: 10.1002/jso.24625. Epub 2017 May 17. J Surg Oncol. 2017. PMID: 28513912 Free PMC article. Review.

See all "Cited by" articles

References

1. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-13 - PMC - PubMed
1. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006;1:289-95 - PubMed
1. Bograd AJ, Suzuki K, Vertes E, et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011;60:1509-27 - PMC - PubMed
1. Suzuki K, Kadota K, Sima CS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011;60:1721-8 - PMC - PubMed
1. Chang K, Pastan I.Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40 - PMC - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations

[1] Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-13 - PMC - PubMed

[2] Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-13 - PMC - PubMed

[3] Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006;1:289-95 - PubMed

[4] Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol 2006;1:289-95 - PubMed

[5] Bograd AJ, Suzuki K, Vertes E, et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011;60:1509-27 - PMC - PubMed

[6] Bograd AJ, Suzuki K, Vertes E, et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011;60:1509-27 - PMC - PubMed

[7] Suzuki K, Kadota K, Sima CS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011;60:1721-8 - PMC - PubMed

[8] Suzuki K, Kadota K, Sima CS, et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 2011;60:1721-8 - PMC - PubMed

[9] Chang K, Pastan I.Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40 - PMC - PubMed

[10] Chang K, Pastan I.Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40 - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Mesothelin-targeted immunotherapies for malignant pleural mesothelioma

Affiliation

Mesothelin-targeted immunotherapies for malignant pleural mesothelioma

Authors

Affiliation

Similar articles

Cited by

References

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources